{
    "nct_id": "NCT03056755",
    "official_title": "BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments",
    "inclusion_criteria": "* Patient has adequate tumor tissue for the analysis of PIK3CA mutational status by a Novartis designated laboratory. It is recommended to provide a tumor sample collected after the most recent progression or recurrence.\n* Advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy\n* Patient has been confirmed as PIK3CA mutant as determined by a certified designated laboratory\n* Patient has histologically and/or cytologically confirmed ER+ and/ or PgR+ BC\n* Patient has confirmed, HER2-negative aBC. HER2-negative defined as a negative in situ hybridization test or an immunohistochemistry (IHC) status of 0, 1+ or 2+.\n* Patients must be diagnosed with aBC, with documented evidence of tumor progression on or after prior treatments. No more than one prior regimen of chemotherapy for the treatment of metastatic disease is permitted. The maximum number of prior therapies for aBC or mBC is limited to two (maintenance therapies, where applicable, must be regarded as part of the main therapy). Patients must have recovered to grade 1 or better from any adverse events (except alopecia) related to previous therapy prior to study entry.\n* Patient has either measurable disease, i.e. at least one measurable lesion as per RECIST v1.1 criteria or if no measurable disease is present than at least one predominantly lytic bone lesion must be present\n* Patient has ECOG performance status of ≤ 2\n* Patient has adequate bone marrow function\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* Patient has received prior treatment with any PI3K inhibitors\n* Patients with an established diagnosis of diabetes mellitus type I or uncontrolled type II\n* Patient has a concurrent malignancy or malignancy within 3 years of study screening period, with the exception of adequately treated basal or squamous cell carcinoma, nonmelanoma skin cancer or curatively resected cervical cancer\n* Patient has received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to enrollment, and who has not recovered to grade 1 or better from related side effects of such therapy (with the exception of alopecia)\n* Patients receiving systemic corticosteroids ≤ 2 weeks prior to treatment with alpelisib\n* History of acute pancreatitis within 1 year of screening or past medical history of pancreatitis\n* Patient has impaired GI function or GI disease that may affect the absorption of study drugs\n* Patient has documented pneumonitis\n* Patients being concurrently treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme Cytochrome P (CYP)3A within the last 5 days prior to study entry\n\nOther inclusion/exclusion criteria may apply",
    "miscellaneous_criteria": "Key"
}